MG
ESPR

Marex Group’s Esperion Therapeutics ESPR Stock Holding History

Marex Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-350,000
Closed -$504K – 743
2025
Q1 		$504K Buy
350,000
+75,000
+27% +$138K 0.01% 331
2024
Q4 		$605K Hold
275,000
– – 0.01% 314
2024
Q3 		$454K Hold
275,000
– – 0.01% 307
2024
Q2 		$611K Buy
275,000
+100,000
+57% +$235K 0.02% 274
2024
Q1 		$469K Buy
175,000
+25,000
+17% +$60.8K 0.02% 261
2023
Q4 		$449K Buy
+150,000
New +$195K 0.02% 325

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Marex Group's ESPR Position: Q2 2025 in Review

Marex Group sold out of Esperion Therapeutics (ESPR) in Q2 2025, closing a stake of 350,000 shares — an estimated $504K sold.

Marex Group first reported a position in ESPR in Q4 2023 and held it in 6 quarters. The position peaked at $611K in Q2 2024. 163 funds tracked by Wall St. Rank hold ESPR as of Q2 2025.

  • Marex Group reported no remaining Esperion Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Marex Group sold 350,000 Esperion Therapeutics shares in Q2 2025, an estimated $504K.
  • Marex Group first reported a position in Esperion Therapeutics in Q4 2023 and held it in 6 quarters.
  • Marex Group's Esperion Therapeutics position peaked at $611K in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2025.

Based on Marex Group's 13F filing for Q2 2025, filed 19 Aug 2025.